Segal-Bendirdjian E - Search Results

1

Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process.

Segal-Bendirdjian E, Jacquemin-Sablon A. Segal-Bendirdjian E, et al. Exp Cell Res. 1995 May;218(1):201-12. doi: 10.1006/excr.1995.1148. Exp Cell Res. 1995. PMID: 7537690

2

[Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis].

Segal-Bendirdjian E, Jacquemin-Sablon A. Segal-Bendirdjian E, et al. Bull Cancer. 1996 May;83(5):371-8. Bull Cancer. 1996. PMID: 8680089 Review. French.

3

Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance.

Ségal-Bendirdjian E, Mannone L, Jacquemin-Sablon A. Ségal-Bendirdjian E, et al. Cell Death Differ. 1998 May;5(5):390-400. doi: 10.1038/sj.cdd.4400357. Cell Death Differ. 1998. PMID: 10200488

4

Nuclear translocation of a leukocyte elastase Inhibitor/Elastase complex during staurosporine-induced apoptosis: role in the generation of nuclear L-DNase II activity.

Belmokhtar CA, Torriglia A, Counis MF, Courtois Y, Jacquemin-Sablon A, Ségal-Bendirdjian E. Belmokhtar CA, et al. Exp Cell Res. 2000 Jan 10;254(1):99-109. doi: 10.1006/excr.1999.4737. Exp Cell Res. 2000. PMID: 10623470

5

Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives.

Markovits J, Larsen AK, Ségal-Bendirdjian E, Fossé P, Saucier JM, Gazit A, Levitzki A, Umezawa K, Jacquemin-Sablon A. Markovits J, et al. Biochem Pharmacol. 1994 Aug 3;48(3):549-60. doi: 10.1016/0006-2952(94)90285-2. Biochem Pharmacol. 1994. PMID: 8068042

6

Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent.

Segal-Bendirdjian E, Coulaud D, Roques BP, Le Pecq JB. Segal-Bendirdjian E, et al. Cancer Res. 1988 Sep 1;48(17):4982-92. Cancer Res. 1988. PMID: 2842043

7

Selective alteration of mitochondrial function by Ditercalinium (NSC 335153), a DNA bisintercalating agent.

Esnault C, Brown SC, Segal-Bendirdjian E, Coulaud D, Mishal Z, Roques BP, Le Pecq JB. Esnault C, et al. Biochem Pharmacol. 1990 Jan 1;39(1):109-22. doi: 10.1016/0006-2952(90)90654-4. Biochem Pharmacol. 1990. PMID: 2297352

8

Recognition by the DNA repair system of DNA structural alterations induced by reversible drug-DNA interactions.

Lambert B, Segal-Bendirdjian E, Esnault C, Le Pecq JB, Roques BP, Jones B, Yeung AT. Lambert B, et al. Anticancer Drug Des. 1990 Feb;5(1):43-53. Anticancer Drug Des. 1990. PMID: 2180423

9

A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation.

Pendino F, Sahraoui T, Lanotte M, Ségal-Bendirdjian E. Pendino F, et al. Leukemia. 2002 May;16(5):826-32. doi: 10.1038/sj.leu.2402470. Leukemia. 2002. PMID: 11986943

10

Evidence for a reverse transcription intermediate for a marked line transposon in tumoral rat cells.

Segal-Bendirdjian E, Heidmann T. Segal-Bendirdjian E, et al. Biochem Biophys Res Commun. 1991 Dec 16;181(2):863-70. doi: 10.1016/0006-291x(91)91270-m. Biochem Biophys Res Commun. 1991. PMID: 1661592

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters